Primary and Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non-small Cell Lung Cancer: An Update

By Ayoola Ayodele   Barochia Amit   Belani Kiran   Belani Chandra P.  

Cancer Investigation, Vol. 30, Iss. 5, 2012-05 ,pp. : 433-446

Informa Healthcare

Access to resources Recommend Favorite

Hypoxia induces resistance to ALK inhibitors in the H3122 non-small cell lung cancer cell line with an ALK rearrangement via epithelial-mesenchymal transition

By                          

International Journal of Oncology, Vol. 45, Iss. 4, 2014-01 ,pp. : 1430-1436

Spandidos Publications

Access to resources Recommend Favorite

Combined gefitinib and pemetrexed overcome the acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer

By        

Molecular Medicine Reports, Vol. 10, Iss. 2, 2014-01 ,pp. : 931-938

Spandidos Publications

Access to resources Recommend Favorite

ALK inhibitors and advanced non-small cell lung cancer (Review)

By                  

International Journal of Oncology, Vol. 45, Iss. 2, 2014-01 ,pp. : 499-508

Spandidos Publications

Access to resources Recommend Favorite

Is EGF receptor–tyrosine kinase inhibitor therapy in non-small-cell lung cancer patients with EGFR mutations the best option?

By Hayashi Hidetoshi   Nakagawa Kazuhiko  

Lung Cancer Management, Vol. 2, Iss. 6, 2013-12 ,pp. : 441-443

Future Medicine

Access to resources Recommend Favorite